Emergent Biosolutions (EBS)
(Delayed Data from NYSE)
$1.92 USD
-0.03 (-1.54%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.92 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
C Value B Growth C Momentum B VGM
Balance Sheet
Fiscal Year End for Emergent Biosolutions Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 112 | 643 | 576 | 622 | 168 |
Receivables | 191 | 158 | 275 | 231 | 275 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 329 | 352 | 351 | 307 | 223 |
Other Current Assets | 48 | 58 | 70 | 37 | 20 |
Total Current Assets | 680 | 1,211 | 1,272 | 1,196 | 686 |
Net Property & Equipment | 383 | 818 | 800 | 644 | 542 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 13 |
Intangibles | 567 | 947 | 830 | 930 | 980 |
Deposits & Other Assets | 194 | 191 | 57 | 113 | 106 |
Total Assets | 1,823 | 3,167 | 2,959 | 2,883 | 2,327 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 112 | 104 | 129 | 136 | 95 |
Current Portion Long-Term Debt | 414 | 957 | 0 | 34 | 13 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 93 | 123 | 140 | 132 | 102 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 33 | 46 | 105 | 83 | 7 |
Total Current Liabilities | 651 | 1,230 | 374 | 385 | 216 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 47 | 72 | 95 | 109 | 150 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 447 | 449 | 809 | 841 | 798 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 29 | 33 | 62 | 102 | 75 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1,174 | 1,784 | 1,340 | 1,436 | 1,239 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 904 | 874 | 829 | 785 | 716 |
Retained Earnings | -22 | 734 | 958 | 727 | 422 |
Other Equity | -6 | 3 | -16 | -25 | -10 |
Treasury Stock | 228 | 228 | 152 | 40 | 40 |
Total Shareholder's Equity | 649 | 1,383 | 1,619 | 1,447 | 1,089 |
Total Liabilities & Shareholder's Equity | 1,823 | 3,167 | 2,959 | 2,883 | 2,327 |
Total Common Equity | 649 | 1,383 | 1,619 | 1,447 | 1,089 |
Shares Outstanding | 51.80 | 49.80 | 53.80 | 53.00 | 51.60 |
Book Value Per Share | 12.53 | 27.77 | 30.09 | 27.30 | 21.09 |
Fiscal Year End for Emergent Biosolutions Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 112 | 88 | 89 | 430 |
Receivables | NA | 191 | 217 | 290 | 156 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 329 | 354 | 354 | 368 |
Other Current Assets | NA | 48 | 62 | 45 | 267 |
Total Current Assets | NA | 680 | 721 | 778 | 1,221 |
Net Property & Equipment | NA | 383 | 395 | 396 | 717 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 567 | 583 | 811 | 827 |
Deposits & Other Assets | NA | 194 | 194 | 195 | 185 |
Total Assets | NA | 1,823 | 1,893 | 2,179 | 2,950 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 112 | 113 | 108 | 124 |
Current Portion Long-Term Debt | NA | 414 | 414 | 455 | 951 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 93 | 100 | 101 | 78 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 33 | 38 | 29 | 63 |
Total Current Liabilities | NA | 651 | 664 | 693 | 1,216 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 47 | 52 | 58 | 60 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 447 | 448 | 448 | 448 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 31 | 23 | 24 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 1,174 | 1,196 | 1,223 | 1,747 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 904 | 900 | 896 | 878 |
Retained Earnings | NA | -22 | 28 | 290 | 551 |
Other Equity | NA | -6 | -3 | -2 | 1 |
Treasury Stock | NA | 228 | 228 | 228 | 228 |
Total Shareholder's Equity | NA | 649 | 697 | 956 | 1,203 |
Total Liabilities & Shareholder's Equity | NA | 1,823 | 1,893 | 2,179 | 2,950 |
Total Common Equity | 0 | 649 | 697 | 956 | 1,203 |
Shares Outstanding | 52.20 | 51.80 | 51.80 | 50.40 | 50.40 |
Book Value Per Share | 0.00 | 12.53 | 13.46 | 18.97 | 23.86 |